Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension of subcutaneous sonelokimab in psoriatic arthritis
2025-522471-28-00Phase 3Authorised
- Sponsor
- MoonLake Immunotherapeutics
- Start
- Feb 2026
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 25
01
Overview
Phase 3, open-label, single-arm trial of sonelokimab in psoriatic arthritis (PsA), sponsored by MoonLake Immunotherapeutics. Primary endpoints: Treatment-emergent adverse events, Serious adverse events and 4 more. Planned start Feb 2026; status: authorised.
02
Drugs
sonelokimab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2025-522471-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522471-28-00.